Global Partners LP GLP
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- +13.36%
- 1 year
- +4.59%
- Open
- 47.43
- Prev close
- 47.91
- Mkt cap
- 1.61B
- Vol
- 62.52K
- Avg vol
- 66.35K
- EPS
- 4.90
- P/E
- 9.68
- Div yield
- 6.51%
More statistics
- Low
- 46.80
- High
- 48.00
- Forward P/E
- 18.98
- Beta
- 1.11
- Short ratio
- 3.41
- Inst. own
- 52.18%
- Dividend
- 3.12
- Ex-div date
- Nov 8, 2026
- Earnings
- Nov 6, 2026
- 50-d avg
- 49.52
- 200-d avg
- 48.00
- 1y target
- 0.00
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:40 PM | 3 days ago |
| RSI: Overbought | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:25 PM | 4 days ago |
| RSI: Oversold | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:05 PM | 4 days ago |
| RSI: Oversold | Oct 28, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
News
6 hours ago fool.com
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Nordisk is one of two leading GLP-1 producers. The company is cutting prices on its GLP-1 drugs as it shifts toward a volume-driven model.
2 days ago fool.com
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF
VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with…
3 days ago seekingalpha.com
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for…
3 days ago businesswire.com
Global Partners Declares Third-Quarter 2026 Cash Distribution of $0.7850 on Common Units
NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared…
3 days ago globenewswire.com
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an…
5 days ago benzinga.com
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.
5 days ago businesswire.com
Charles River Leverages Virtual Control Groups in GLP Studies
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
5 days ago prnewswire.com
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27%…
1 week ago businesswire.com
Global Partners LP to Host Third-Quarter 2026 Financial Results Conference Call on November 6, 2026
NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its third-quarter 2026 financial results before the market…
1 week ago etftrends.com
What Is the Peptide Economy? Beyond the GLP-1 Boom
GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.
1 week ago newsfilecorp.com
The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line
Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development Highlights Exclusive manufacturing rights…
1 week ago globenewswire.com
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027…
1 week ago zacks.com
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
1 week ago accessnewswire.com
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has…
1 week ago zacks.com
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms.
1 week ago zacks.com
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
1 week ago zacks.com
Are Investors Undervaluing Global Partners (GLP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
1 week ago globenewswire.com
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress
SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight…
1 week ago seekingalpha.com
Hims & Hers Health: The Lollapalooza Effect Of GLP-1s
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, sticky consumer habits. HIMS benefits from powerful psychological drivers—pain…
2 weeks ago globenewswire.com
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham
-
2 months ago benzinga.com
Global Partners Q2 EPS $1.86 Beats $1.24 Estimate, Sales $6.792B Miss $7.507B Estimate
Global Partners (NYSE:GLP) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.24 by 50 percent. This is a 238.18 percent increase over earnings of $0.55…
-
5 months ago benzinga.com
Global Partners Q1 EPS $1.85 Beats $0.33 Estimate, Sales $5.322B Miss $6.976B Estimate
Global Partners (NYSE:GLP) reported quarterly earnings of $1.85 per share which beat the analyst consensus estimate of $0.33 by 460.61 percent. This is a 413.89 percent increase over earnings of…
-
8 months ago benzinga.com
Stifel Maintains Hold on Global Partners, Raises Price Target to $46
Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and raises the price target from $45 to $46.
8 months ago benzinga.com
Global Partners: Q4 Earnings Insights
Global Partners: Q4 Earnings Insights
8 months ago benzinga.com
Earnings Scheduled For February 27, 2026
Earnings Scheduled For February 27, 2026
8 months ago benzinga.com
Nasdaq Down Over 1% As Nvidia Shares Fall: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone
Market sentiment declines, Nasdaq falls 1%. Nvidia down 5%, Salesforce up 4% in earnings. Initial jobless claims rise.
8 months ago benzinga.com
Dell, Block And 3 Stocks To Watch Heading Into Friday
U.S. stock futures lower, Carter's and Dell report earnings, Global Partners and Block announce earnings, and Zscaler cuts sales guidance.
-
11 months ago benzinga.com
Stifel Maintains Hold on Global Partners, Lowers Price Target to $45
Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and lowers the price target from $53 to $45.
-
11 months ago benzinga.com
Global Partners Q3 EPS $0.66 Misses $1.09 Estimate, Sales $4.694B Miss $7.211B Estimate
Global Partners (NYSE:GLP) reported quarterly earnings of $0.66 per share which missed the analyst consensus estimate of $1.09 by 39.45 percent. This is a 43.59 percent decrease over earnings of…
11 months ago benzinga.com
Earnings Scheduled For November 7, 2025
Earnings Scheduled For November 7, 2025
-
12 months ago benzinga.com
A Look Ahead: Global Partners's Earnings Forecast
A Look Ahead: Global Partners's Earnings Forecast
1 year ago benzinga.com
Top 3 Energy Stocks That May Rocket Higher In October
Top 3 Energy Stocks That May Rocket Higher In October
1 year ago benzinga.com
Wall Street Rallies After US Seals First Trade Deal: 'You Better Go Out And Buy Stock,' Trump Says
U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement with the United Kingdom, igniting optimism about further global deals — especially with China — and…
-
1 year ago benzinga.com
Earnings Scheduled For February 28, 2025
Earnings Scheduled For February 28, 2025
-
2 years ago benzinga.com
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
-
2 years ago benzinga.com
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
-
3 years ago benzinga.com
Earnings Scheduled For August 4, 2023
Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.
-
3 years ago benzinga.com
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
-
3 years ago benzinga.com
5 Value Stocks To Watch In The Energy Sector
5 Value Stocks To Watch In The Energy Sector
-
3 years ago benzinga.com
Earnings Scheduled For November 4, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings…
-
4 years ago benzinga.com
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning trading, 251 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Tuesday morning saw 244 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday's morning session saw 275 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 166 companies hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 253 companies set new 52-week highs.